Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 20/20 | 0.73 |
| ▸ | HDAC4 | P56524 | 20/20 | 0.73 |
| ▸ | HDAC1 | Q13547 | 20/20 | 0.73 |
| ▸ | HDAC7 | Q8WUI4 | 20/20 | 0.73 |
| ▸ | HDAC2 | Q92769 | 20/20 | 0.73 |
| ▸ | HDAC10 | Q969S8 | 20/20 | 0.73 |
| ▸ | HDAC11 | Q96DB2 | 20/20 | 0.73 |
| ▸ | HDAC8 | Q9BY41 | 20/20 | 0.73 |
| ▸ | HDAC6 | Q9UBN7 | 20/20 | 0.73 |
| ▸ | HDAC9 | Q9UKV0 | 20/20 | 0.73 |
| ▸ | HDAC5 | Q9UQL6 | 20/20 | 0.73 |
| ▸ | KDR | P35968 | 14/20 | 0.73 |
| ▸ | EGFR | P00533 | 3/20 | 0.62 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17520353 | 0.91 | KDR (0.73) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL19220774 | 0.91 | HDAC3 (0.70) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL19220786 | 0.90 | HDAC3 (0.69) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL19220783 | 0.89 | HDAC3 (0.67) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL19220792 | 0.88 | KDR (0.69) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL19220794 | 0.86 | KDR (0.64) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL7865988 | 0.83 | KDR (0.80) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL7866068 | 0.83 | KDR (0.80) | KDREGFR | |
| SCHEMBL19220775 | 0.83 | RET (0.64) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Hydrochloric Acid SCHEMBL7867718 | 0.82 | KDR (0.78) | KDREGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170226099-A1 | QUINAZOLINE DERIVATIVE | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226099-A1 | QUINAZOLINE DERIVATIVE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 | HDAC3 1036/4885HDAC4 933/4885HDAC1 1112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.